Long-term clinical outcomes of differentiated thyroid cancer patients with biochemical incomplete response after initial radioiodine therapy, a single-center, retrospective analysis
Key Points
Biochemical incomplete response indicates potential progression in patients with thyroid cancer.
Key metrics are sTg levels higher than 50.0 ng/mL and T3b-T4 stages, pointing towards disease progression.
Clinical markers were identified through a retrospective analysis of patient outcomes from initial treatments.
These findings highlight the need for intensified monitoring and possible re-evaluation of therapeutic strategies.
Abstract
sTg≥50.0 ng/mL and T3b-T4 stage are robust, clinically accessible markers identifying PD among BIR patients, warranting intensified surveillance and potentially earlier therapeutic reconsideration.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Long-term clinical outcomes of differentiated thyroid cancer patients with biochemical incomplete response after initial radioiodine therapy, a single-center, retrospective analysis | Synapse